Independent directory Public ClinicalTrials.gov records United States
Location Directory

Clinical trials in Aurora, Colorado

This page shows live ClinicalTrials.gov search results for Aurora, Colorado, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 10:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
7453
Shown on this page
12
Current sort
Recently updated
Location scope
Aurora, CO
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Aurora, Colorado. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 805–816 of 7,453 matching trials in Aurora, CO.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Aurora

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Conditions
Breast Cancer, Early Breast Cancer
Interventions
Camizestrant, Tamoxifen, Anastrozole, Letrozole, Exemestane
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
4,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
126
States / cities
Birmingham, Alabama • Dothan, Alabama • Anchorage, Alaska + 110 more
Conditions
Prostate Cancer
Interventions
enzalutamide, abiraterone acetate, prednisone, Leuprolide acetate
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
46
States / cities
Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 38 more
Conditions
Type 1 Diabetes
Interventions
High Dose SAB-142, Low Dose SAB-142, Placebo
Drug · Other
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
5 Years to 40 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
22
States / cities
San Francisco, California • San Jose, California • Aurora, Colorado + 19 more
Conditions
Advanced Solid Tumors, Breast Cancer Recurrent, Ovarian Cancer, High-grade Serous Ovarian Carcinoma, Triple Negative Breast Cancer, sqNSCLC, Squamous Non-small-cell Lung Cancer
Interventions
ATX-295, ATX-295 and bevacizumab (or biosimilar)
Drug
Lead sponsor
Accent Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
11
States / cities
Aurora, Colorado • Sarasota, Florida • Detroit, Michigan + 8 more
Conditions
Adult Growth Hormone Deficiency, Mild Traumatic Brain Injury
Interventions
Somatropin, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 55 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 13 more
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
acalabrutinib, placebo, Prednisone, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 75 Years
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
32
States / cities
Tucson, Arizona • Little Rock, Arkansas • Irvine, California + 28 more
Conditions
Hemorrhagic Stroke, Aneurysm, Intracranial, Saccular Aneurysm, Fusiform Aneurysm, Brain Aneurysm
Interventions
Flow diversion
Device
Lead sponsor
phenox Inc.
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 21 more
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Luveltamab tazevibulin
Drug
Lead sponsor
Sutro Biopharma, Inc.
Industry
Eligibility
1 Day to 12 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 19 more
Conditions
Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Neuroblastoma
Interventions
Biopsy Procedure, Bone Marrow Aspiration, Bone Marrow Biopsy, Carboplatin, Clinical Observation, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Magnetic Resonance Imaging, Ultrasound
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 18 Months
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
193
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 147 more
Conditions
Secondary Progressive Multiple Sclerosis (SPMS)
Interventions
Remibrutinib (blinded), Placebo, Remibrutinib (Open label)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more
Conditions
Multiple Sclerosis
Interventions
Frexalimab, MRI contrast-enhancing preparations
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 60 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
34
States / cities
Cullman, Alabama • Homewood, Alabama • Phoenix, Arizona + 29 more
Conditions
Higher-risk Myelodysplastic Syndrome
Interventions
Lisaftoclax (APG-2575), Azacitidine Injection, Placebo
Drug · Other
Lead sponsor
Ascentage Pharma Group Inc.
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 36 more